Our Pipeline - Pioneering Mitochondrial DNA Technology
In addition to the Prostate Core Mitomic Test™, MDNA Life Sciences is using our proprietary Mitomic Technology™ to develop an advanced pipeline of product solutions for disease detection and prognosis. All of these novel tests will offer high accuracy, and most will be non-invasive. Mitomic Tests are currently in development for the early detection or characterization of:
- Prostate cancer
- Ovarian cancer
- Lung cancer
- Pancreatic cancer
Prostate Mitomic Test is a blood-based screening test for the accurate prediction of prostate cancer following an elevated PSA level. This prostate cancer-specific assay is used to stratify which patients need or do not need to undergo a prostate gland biopsy. Due to well-known limitations with PSA testing alone, Prostate Mitomic Test will enable urologists to make more accurate biopsy decisions.
Endometrial Mitomic Test is a blood-based screening test to detect endometriosis in high-risk patients and women of reproductive age. The current standard for the diagnosis of endometriosis is through laparoscopic surgery and an ectopic endometrial tissue sample. Endometrial Mitomic Test may provide physicians with a non-invasive, non-surgical, highly accurate alternative to detect endometriosis.